December 14: Psychedelic Assisted Psychotherapy for Mental Disorders

$35.00

Date:
Tuesday, December 14, 2021

Time:
0900 PT | 1000 MT | 1100 CT/SK | 1200 ET | 1300 AT

Duration:
120 minutes including a Q&A

Includes:
• A certificate of completion
• The live webinar event if registering prior to commencement
• The on-demand recording to watch at your convenience
• A handout in PDF format for viewing or self-printing

See below for the outline, speaker biography, and more.

SKU: Psychedelic 1 Categories: , , , , Tag:

Description

Date:
Tuesday, December 14, 2021

Time:
0900 PT | 1000 MT | 1100 CT/SK | 1200 ET | 1300 AT

Duration:
120 minutes including a Q&A

Includes:
• A certificate of completion
• The live webinar event if registering prior to commencement
• The on-demand recording to watch at your convenience
• A handout in PDF format for viewing or self-printing

Objectives:
•  To better understand the limitations of existing modalities to treat common mental health and wellness challenges
•  To understand the history of altered states of consciousness in treating mental disorders
•  To appreciate the potential complementary role of psychedelic assisted psychotherapy in the treatment of mental disorders
•  To understand the evidence for the use of MDMA assisted psychotherapy in the treatment of post traumatic stress disorder
•  To understand the evidence for the use of psilocybin assisted psychotherapy in the treatment of a range of mental disorders

Description:
While experimentation with psychedelics gave its early researchers reason to have faith that use of these drugs had more value than recreation, it has just been the last two decades that have inspired a new wave of research involving mental health. As more and more clinical research described beneficial effects of psychedelics, research became more focused and has come to include psychedelic assisted psychotherapy for mental disorders. As limitations still exist in current modalities to treat mental health disorders, its time to take a closer look at the successes and limits of of psychedelics in mental health; to understand what works, when, and why and how to support clients undergoing psychedelic assisted psychotherapy.

Who Should Attend?:
• Physicians, Psychologists, Mental Health Nurses, Therapists, Psychotherapists
• Social Workers & Allied Professional Staff in Psychiatric settings
• Primary Care Physicians & Nurses; MH Staff in Community Settings
• Intake & Frontline Staff; Mental Health Managers and Educators

Dr. Evan Wood, MD, PhD, ABIM, FASAM, FRCPC, ABAM

Dr. Evan Wood is a physician and researcher based in British Columbia. He has previously served in a range of leadership roles within the health authority, university and hospital systems including being a Professor of Medicine and Canada Research Chair at the University of British Columbia where he was the Executive Director of the BC Centre on Substance Use. He is currently the Chief Medical Officer of Numinus Wellness, a mental wellness company focussed on expanding access to safe and evidence-based psychedelic assisted psychotherapy.